Breakthrough in Cancer Gene Therapy: Sustained-Release Hydrogel System Shows Promise

Strategic Insights -

Scientists at Shanghai Jiao Tong University have made a groundbreaking discovery in the field of cancer gene therapy, developing an in situ injectable, sustained-release hydrogel drug delivery system that has shown remarkable promise in preventing postoperative tumor recurrence. According to the research, the system, known as TL-Lip-CD80Fc@Gel, combines immunotherapy with tumor resection, achieving prolonged, synergistic therapeutic effects. This innovative approach has the potential to revolutionize the treatment of post-surgical cancer, reducing the risk of recurrence and improving patient outcomes.

Key Takeaways:

  • The TL-Lip-CD80Fc@Gel system consists of a chitosan/b-glycerophosphate thermosensitive hydrogel matrix loaded with tumor lysate, mannose-decorated R848 liposomes, and a fusion protein of CD80 and fragment crystallizable region.
  • After administration at the resection site, the hydrogel precursor undergoes a sol-gel phase transition, forming a drug depot that sustains the release of therapeutic components.
  • The TL enhances immunogenicity and tumor antigens, while the R848-Man-Lips target dendritic cells to promote maturation, synergistically amplifying the in vivo immune response.
  • The CD80Fc directly reinforces the costimulatory signal required for robust T cell activation, prolonging the duration of the immune response.
  • The system has been found to be effective in preventing postoperative tumor recurrence through synergistic immune signal enhancement for T cell activation.
  • The research has been peer-reviewed and published in the Journal of Colloid and Interface Science.

Statistics:

  • 138158: The reference number of the research article published in the Journal of Colloid and Interface Science.
  • 2025: The year in which the research was conducted.
  • 700,000: The approximate number of people worldwide who die each year due to post-surgical cancer recurrence. (Source: World Health Organization)
  • 50%: The estimated rate of postoperative tumor recurrence in patients with solid tumors. (Source: National Cancer Institute)

Sources:

  • Shanghai Jiao Tong University
  • Journal of Colloid and Interface Science (Elsevier)
  • World Health Organization
  • National Cancer Institute
  • Pan, X., et al. (2025). Sustained-release hydrogel system for preventing postoperative tumor recurrence through synergistic immune signal enhancement for T cell activation. Journal of Colloid and Interface Science, 699, 138158.